Meet our Partnering Advisory Team

With larger partnering discussions coming into view, we recently recruited our Partnership Advisory Team, comprised of executives with senior leadership experience in value creation and partnership in the pharmaceutical sector.

Angus served as CEO of Shire Plc for five years until his retirement in 2013 and was a member of its board of directors for thirteen years. Earlier in his career, Angus held roles of increasing responsibility at ICI, Zeneca, and AstraZeneca.

He is the Chairman of Mallinckrodt, a UK-based leading global specialty pharmaceutical company, and of Revance Therapeutics, a biotechnology company focused on aesthetic medicine. Angus is also an independent director at TherapeuticsMD, an innovative women’s healthcare company, and Lineage Therapeutics, a leader in pluripotent stem cell treatments.


DBA (Honorary)  Coventry University, UK
Chartered Accountant  Institute of Chartered Accountants in England and Wales

Angus led Shire through nine mergers and acquisitions, evolving the company into a global leader. Shire’s acquisitions during his tenure as CEO had a cumulative value exceeding $4 billion.

“I’m always up for advising a company that has the potential to deliver innovative treatments for patients!”

As a biopharma executive and lawyer, Andrew structures deals to facilitate the development and commercialization of new drugs and therapies. He has negotiated and managed licensing and joint venture relationships for Baxter International and other companies on five continents.

He is a board member of Aclaris Therapeutics, Synthorx and Motif Bio, and chairs the board of Landec Inc, a leading innovator in diversified health and wellness solutions.

JD  Stanford Law School, USA

Andrew played an instrumental role in the sale of Medivation to Pfizer for $14 billion, the sale of InterMune to Roche for more than $8 billion, and the sale of ImClone to Eli Lilly for $6.5 billion.

“This is a company that’s addressing a problem that afflicts every human being.”

Dominique has more than 35 years of leadership experience successfully commercializing a broad range of biotech and pharmaceutical products in the US and internationally. He served as Senior Vice President and Chief Marketing Officer of Alexion in 2014-2015.

He is President and CEO of PDL BioPharma, a U.S. public company managing a portfolio of healthcare assets. He is a board member of PDL and of Evofem Biosciences.



Dominique was responsible for relaunching the growth of Amgen’s Inflammation Business Unit in 2011-2013, including Enbrel, a leading treatment for rheumatoid arthritis with US revenues exceeding $4 billion.

“The control of inflammation is key to addressing a wide range of unmet medical needs.”

In his most recent role, Rami headed the outreach and partnership efforts at Spectrum Therapeutics, a Canopy Growth Corporation Company that focuses on cannabinoid therapeutics. He had previously led the company’s research and development effort, involving several clinical development programs and discovery initiatives addressing nervous system disorders (including pain) and cancer supportive care.

Over his career, Rami has worked with large biopharmaceutical companies, startups, consulting firms, governments, and academic institutions in the US, Canada, and Europe.


PhD Experimental Medicine  McGill University, Canada
MBA  Concordia University, Canada

Order of Pharmacists of Quebec, Canada

Rami and his teams have identified and evaluated hundreds of products and product candidates in clinical and preclinical development.

“Pain is a ‘screaming’ and multi-faceted medical need, and it’s central to successful disease management. I believe that Antibe’s research program is a path to better medicines for pain.”